SkinSpirit Launches PDRN Salmon DNA Regenerative Treatment
SEATTLE, July 1, 2026 SkinSpirit, a leading U.S. provider of medical aesthetic treatments, has expanded its regenerative aesthetics portfolio...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SEATTLE, July 1, 2026 SkinSpirit, a leading U.S. provider of medical aesthetic treatments, has expanded its regenerative aesthetics portfolio...
